Fusion Gene	Target	Disease	Indication(s)	Product reference
AML1-ETO	t(8;21)	AML	Monitoring	FQPP-01
CBFB-MYH11 type A	inv(16)	AML	Monitoring	FQPP-02
PML-RARA bcr1	t(15;17)	AML	Monitoring	FQPP-05-CE
PML-RARA bcr2	t(15;17)	AML	Monitoring	FQPP-06
PML-RARA bcr3	t(15;17)	AML	Monitoring	FQPP-07
BCR-ABL mbcr/ABL	t(9;22)	ALL	Monitoring	FQPP-09-ABL
BCR-ABL mbcr/BCR	t(9;22)	ALL	Monitoring	FQPP-09-BCR
BCR-ABL mbcr/GUS	t(9;22)	ALL	Monitoring	FQPP-09-GUS
BCR-ABL  Mbcr/ABL	t(9;22)	CML/ALL	Monitoring	FQPP-10-ABL
BCR-ABL  Mbcr/BCR	t(9;22)	CML/ALL	Monitoring	FQPP-10-BCR
BCR-ABL  Mbcr/GUS	t(9;22)	CML/ALL	Monitoring	FQPP-10-GUS
BCR-ABL Mbcr Mega Kit/ABL	t(9;22)	CML/ALL	Monitoring	FQPP-10M-ABL
BCR-ABL Mbcr Mega Kit/BCR	t(9;22)	CML/ALL	Monitoring	FQPP-10M-BCR
BCR-ABL Mbcr Mega Kit/GUS	t(9;22)	CML/ALL	Monitoring	FQPP-10M-GUS
BCR-ABL  Mbcr Dx-CE	t(9;22)	CML/ALL	Monitoring	FQPP-10-DX-CE*
BCR-ABL  Mbcr EZ-CE	t(9;22)	CML/ALL	Monitoring	FQPP-10-EZ-CE†*
RT-Dx Kit				RT-01-CE†*
TEL – AML 1 e4e11	t(12;21)	ALL	Monitoring	FQPP-11

 * CE marked kits for In Vitro Diagnostic Use
† Available as a separated reference 

JAK2 mutation assays allow qualitative and quantitative detection of the JAK2 V617F mutation from genomic DNA isolated from peripheral blood. These tests improve the classification of Philadelphia Negative (Ph-) myeloproliferative neoplasms.

MPL MutaScreen^TM technology uses PCR amplification on genomic DNA with specific and sensitive analysis of MPL W515L and MPL W515K mutations in two different reactions.

Gene Mutation	Description	Indication(s)	Disease	Product Reference
JAK2 V617F Mutation	JAK2 MutaScreen Kit	Screening Diagnosis Monitoring†	MPDs	MSPP-01*
JAK2 V617F Mutation	JAK2 MutaScreen Mini Kit	Screening Diagnosis	MPDs	MSPP-02*
JAK2 V617F Mutation	JAK2 MutaScreen Kit & Ref. Scale	Screening Diagnosis	MPDs	MSPP-03*
JAK2 V617F Mutation	JAK2 MutaQuant Kit (Quantitative)	Screening Diagnosis	MPDs	MQPP-01
MPL W515L/K Mutations	MPL W515L/K MutaScreen Kit	Screening	MPDs	MSPP-10

* CE marked kits for In Vitro Diagnostic Use
† Under clinical evaluation.

Product	Localization	Disease	Indication(s)	Product Reference
WT1	Chromosome 11p13	AML, CML, MDS	Monitoring *	PQPP-02
BAALC	Chromosome 8q22.3	AML (normal karyotype), ALL	Prognosis	PQPP-03
CLLU1	Chromosome 12q22	CLL	Prognosis	PQPP-04

 * Under clinical evaluation.

FusionQuant ® Standards are intended for the quantification of individual fusion genes or control genes by RQ-PCR. Each Fusion Gene Standard is comprised of five vials containing precisely controlled dilutions of a given fusion gene. Standard dilutions: 10¹, 10², 10³, 10⁵ , 10⁶ copies in 5µl.

Gene Mutation	Localization	Disease	Indication(s)	Product Reference
NPM1 Mutation A cDNA	Chromosome 5q35	AML (normal karyotype)	Prognosis	MQRS-01*
NPM1 Mutation A gDNA	Chromosome 5q35	AML (normal karyotype)	Prognosis	MQRS-01G**
NPM1 Mutation B & D cDNA	Chromosome 5q35	AML (normal karyotype)	Prognosis	MQRS-02*
NPM1 Mutation B & D gDNA	Chromosome 5q35	AML (normal karyotype)	Prognosis	MQRS-02G**

 *For quantification of cDNA
**For quantification of gDNA

Control cell lines are ideal tools for the control of total RNA extraction and transcription steps in the context of specific rearrangement detection by quantitative PCR. One vial of control cell line should be processed in parallel with one batch of samples using the same reagents and protocols.

Product	Description	Indication(s)	Product Reference
BCR-ABL Mbcr Control Kit	Control Cell Lines *	Monitoring	CLCK-01
High BCR-ABL Mbcr Positive Control	Control Cell Lines *	Monitoring	PCCL-01
Low BCR-ABL Mbcr Positive Control	Control Cell Lines *	Monitoring	PCCL-03
Negative BCR-ABL Mbcr & mbcr	Control Cell Lines *	Monitoring	PCCL-05

Combined with Ipsogen’s standardised FusionQuant and ProfileQuant technologies, IpsoQuant Software provides automatic extraction, analysis and storage of data, including analysis reports with historical data from previous tests.